Anakinra treatment in patients with gout and type 2 diabetes

被引：0
作者：
Antonio Vitale
Luca Cantarini
Donato Rigante
Marco Bardelli
Mauro Galeazzi
机构：
[1] University of Siena,Research Center of Systemic Autoimmune and Autoinflammatory Diseases and Behçet’s Disease Clinic
[2] Università Cattolica Sacro Cuore,Institute of Pediatrics
来源：
Clinical Rheumatology | 2015年 / 34卷
关键词：
Anakinra; Autoinflammatory disorders; Gout; Interleukin (IL)-1β; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
We report three Caucasian patients affected by gout and type 2 diabetes, who were treated with the recombinant nonglycosylated human interleukin-1 receptor antagonist anakinra (100 mg/day subcutaneously) after an unsatisfactory or incomplete response to urate-lowering therapy, colchicine, nonsteroidal anti-inflammatory drugs, and prednisone. The remarkable clinical improvement in joint symptoms within 24 h and in glycemic control during a 6-month period gives anakinra a potential therapeutic role in the management of gout and type 2 diabetes. When anakinra was discontinued, a gout attack occurred within 3–25 days in all three patients. The contribution of anakinra in the treatment of such syndromes is encouraging, but requires further studies to establish its long-term efficacy.
引用
收藏
页码：981 / 984
页数：3
相关论文
共 94 条
  • [1] Joost PH(2006)The inflammasome: a linebacker of innate defense N Engl J Med 355 730-732
  • [2] van Der Meer JW(2006)Gout-associated uric acid crystals activate the NALP3 inflammasome Nature 440 237-241
  • [3] Martinon F(2013)Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis J Clin Rheumatol 19 19-29
  • [4] Pétrilli V(2003)Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes Diabetes 52 102-110
  • [5] Mayor A(2006)Inflammation and insulin resistance J Clin Invest 116 1793-1801
  • [6] Tardivel A(2004)Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets Proc Natl Acad Sci U S A 101 8138-8143
  • [7] Tschopp J(2011)Neutralizing interleukin-1beta (IL-1beta) induces beta-cell survival by maintaining PDX1 protein nuclear localization J Biol Chem 286 17144-17155
  • [8] Cronstein BN(2010)Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study Diabetes 59 1222-1227
  • [9] Sunkureddi P(2011)Blocking interleukin-1β in acute and chronic autoinflammatory diseases J Intern Med 269 16-28
  • [10] Butler AE(2007)A pilot study of IL-1 inhibition by anakinra in acute gout Arthritis Res Ther 9 R28-1848
12345678910